Benzbromarone

Summary

Benzbromarone (CHEMBL388590) is an approved small-molecule uricosuric drug (ATC M04AB03) targeting PIEZO1; indicated across 3 conditions including gout.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M04AB03
• Targets: 1 (PIEZO1)
• Indications: 3 conditions
• Clinical trials: 10
• Chemistry: 424.1 Da · C17H12Br2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL388590
Name	Benzbromarone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2333
ChEBI	CHEBI:3023
ATC	M04AB03
Molecular formula	C17H12Br2O3
Molecular weight	424.1
InChIKey	WHQCHUCQKNIQEC-UHFFFAOYSA-N

SMILES: CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br

IUPAC name: (3,5-dibromo-4-hydroxyphenyl)-(2-ethyl-1-benzofuran-3-yl)methanone

ChEBI definition: 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.

Pharmacological roles (ChEBI): uricosuric drug.

Also known as: Benzbromaron, Benzbromarona, Benzbromarone, Benzpromarone, Desuric, L-2214, MJ 10061, MJ-10061, Narcaricin mite, NSC-85433, Uroleap, benzbromarone

Patent coverage: 2,972 distinct patent families (8,245 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 8,136 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
PIEZO1	Piezo1	Inhibition	5.4	1.2%	Q92508

Broader ChEMBL bioactivity targets: 70 (assay-derived). Sample: Polymerase acidic protein, Microtubule-associated protein tau, Ubiquitin carboxyl-terminal hydrolase 2, Streptokinase A, Fructose-bisphosphate aldolase, Prelamin-A/C, ATP-dependent DNA helicase Q1, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Protein phosphatase EYA2, Leucine aminopeptidase, Solute carrier family 22 member 6, Protein RecA, Replicative DNA helicase DnaB, ATP-binding cassette sub-family C member 4, 5-hydroxytryptamine receptor 2B, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor, Alpha-2B adrenergic receptor, Thyroid hormone receptor beta, Thyrotropin receptor.

Bioactivity

ChEMBL activities: 87 potent at pChembl ≥ 5 of 141 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CYP2C9	8.1	Potency	7.9	nM	CHEMBL_ACT_5037531
CYP2C9	8.1	AC50	7.94	nM	CHEMBL_ACT_6000008
TTR	7.82	Kd	15	nM	CHEMBL_ACT_29145686
CYP2C9	7.8	IC50	16	nM	CHEMBL_ACT_7620789
CYP2C9	7.72	Ki	19	nM	CHEMBL_ACT_1842740
CYP2C9	7.72	Ki	19	nM	CHEMBL_ACT_2069455
CYP2C9	7.72	Ki	19	nM	CHEMBL_ACT_2192900
SLC22A12	7.66	IC50	22	nM	CHEMBL_ACT_16663682
SLC22A12	7.58	IC50	26	nM	CHEMBL_ACT_6172511
SLC22A12	7.46	IC50	34.5	nM	CHEMBL_ACT_22899000
SLC22A12	7.46	IC50	35	nM	CHEMBL_ACT_6172582
CHRM2	7.43	AC50	37.3	nM	CHEMBL_ACT_25195226
CYP2C9	7.4	Potency	39.8	nM	CHEMBL_ACT_5016891
CYP2C9	7.39	IC50	41	nM	CHEMBL_ACT_22898987
CYP2C9	7.39	IC50	41	nM	CHEMBL_ACT_22934391
LMNA	7.35	Potency	44.7	nM	CHEMBL_ACT_3639553
AKR1C1	7.32	IC50	48	nM	CHEMBL_ACT_2510731
SLC22A12	7.32	IC50	48	nM	CHEMBL_ACT_26044639
SLC22A12	6.92	IC50	120	nM	CHEMBL_ACT_18070378
SLC22A12	6.72	IC50	190	nM	CHEMBL_ACT_22898989
ABCC1	6.72	Ki	190	nM	CHEMBL_ACT_6312900
ABCG2	6.7	IC50	200	nM	CHEMBL_ACT_24777402
TTR	6.7	Kd	200	nM	CHEMBL_ACT_25481501
SLC22A12	6.66	IC50	220	nM	CHEMBL_ACT_20627788
SLC22A12	6.52	IC50	300	nM	CHEMBL_ACT_2147003
SLC22A12	6.52	IC50	300	nM	CHEMBL_ACT_24991042
ABCG2	6.47	IC50	340	nM	CHEMBL_ACT_25577211
SLC22A12	6.41	IC50	390	nM	CHEMBL_ACT_29189366
SLC22A12	6.28	IC50	530	nM	CHEMBL_ACT_25577203
SLC22A12	6.28	IC50	530	nM	CHEMBL_ACT_26124075
SLC22A12	6.26	IC50	550	nM	CHEMBL_ACT_27438092
USP2	6.2	Potency	631	nM	CHEMBL_ACT_4752012
SLC22A12	6.12	IC50	750	nM	CHEMBL_ACT_17656134
PPARG	6.03	AC50	940	nM	CHEMBL_ACT_25114150
HIF1A	6	Potency	1000	nM	CHEMBL_ACT_4117734
HIF1A	6	Potency	1000	nM	CHEMBL_ACT_4519785
HTR2B	5.94	Ki	1148	nM	CHEMBL_ACT_7599296
MAPK14	5.91	IC50	1235	nM	CHEMBL_ACT_7599273
HTR2B	5.82	AC50	1530	nM	CHEMBL_ACT_25227386
PDE4D	5.75	AC50	1777	nM	CHEMBL_ACT_25185173
HTR2B	5.74	IC50	1804	nM	CHEMBL_ACT_7599295
MAPK1	5.71	IC50	1946	nM	CHEMBL_ACT_7599271
PDE4D	5.68	IC50	2100	nM	CHEMBL_ACT_26196241
SLC22A6	5.67	IC50	2120	nM	CHEMBL_ACT_25577209
ALB	5.66	Kd	2200	nM	CHEMBL_ACT_29145730
ADRA1A	5.58	AC50	2650	nM	CHEMBL_ACT_25217960
P9WMR3	5.56	AC50	2749	nM	CHEMBL_ACT_6596054
CHRM2	5.55	AC50	2800	nM	CHEMBL_ACT_25213597
TTR	5.55	Ki	2800	nM	CHEMBL_ACT_29145615
ADORA3	5.53	Ki	2952	nM	CHEMBL_ACT_7620720
ABCB11	5.52	AC50	3000	nM	CHEMBL_ACT_25126944
HIF1A	5.5	Potency	3162	nM	CHEMBL_ACT_4128830
HIF1A	5.5	Potency	3162	nM	CHEMBL_ACT_4520652
CYP2C19	5.43	Ki	3700	nM	CHEMBL_ACT_1842738
ADRA2A	5.43	AC50	3742	nM	CHEMBL_ACT_25219753
PGR	5.42	AC50	3800	nM	CHEMBL_ACT_25222038
ABCC1	5.4	IC50	4000	nM	CHEMBL_ACT_12539428
TSHR	5.4	Potency	3981	nM	CHEMBL_ACT_3914858
HIF1A	5.4	Potency	3981	nM	CHEMBL_ACT_4126845
HIF1A	5.4	Potency	3981	nM	CHEMBL_ACT_4520256
TSHR	5.4	Potency	3981	nM	CHEMBL_ACT_4747019
ABCC1	5.4	IC50	4000	nM	CHEMBL_ACT_6312894
ADORA3	5.38	AC50	4189	nM	CHEMBL_ACT_25134060
CYP2J2	5.37	IC50	4260	nM	CHEMBL_ACT_15461593
SLC22A6	5.34	IC50	4600	nM	CHEMBL_ACT_11001478
PPARG	5.32	IC50	4811	nM	CHEMBL_ACT_3798657
P43367	5.31	IC50	4880	nM	CHEMBL_ACT_4084568
ADORA3	5.28	IC50	5222	nM	CHEMBL_ACT_7620719
TTR	5.24	IC50	5700	nM	CHEMBL_ACT_25481486
CYP2C19	5.2	Potency	6310	nM	CHEMBL_ACT_4018401
P10520	5.18	EC50	6550	nM	CHEMBL_ACT_4905707
SLC22A12	5.17	IC50	6800	nM	CHEMBL_ACT_22898886
ESR1	5.12	AC50	7600	nM	CHEMBL_ACT_25116309
CYP2C19	5.1	Potency	7943	nM	CHEMBL_ACT_4015437
P43367	5.1	IC50	7972	nM	CHEMBL_ACT_4083577
CYP2C19	5.1	AC50	7943	nM	CHEMBL_ACT_6039819
EYA3	5.08	IC50	8300	nM	CHEMBL_ACT_18715761
EYA3	5.08	IC50	8300	nM	CHEMBL_ACT_19360999
EYA3	5.08	IC50	8300	nM	CHEMBL_ACT_27629048
Q63344	5.05	IC50	9000	nM	CHEMBL_ACT_11000518
THRB	5.05	Kd	9000	nM	CHEMBL_ACT_29145734
LMNA	5.05	Potency	8912	nM	CHEMBL_ACT_3663489
HSPD1	5.04	IC50	9100	nM	CHEMBL_ACT_19209408
HRH1	5.04	AC50	9192	nM	CHEMBL_ACT_25116945
PDE3A	5.03	AC50	9400	nM	CHEMBL_ACT_25190538
P9WMR3	5.02	AC50	9465	nM	CHEMBL_ACT_7395715
MAPK1	5	Potency	10000	nM	CHEMBL_ACT_4543148

Target pathways

Aggregated over 1 target gene(s): PIEZO1.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	1	PIEZO1
Mechanical load activates signaling by PIEZO1 and integrins in osteocytes	1	PIEZO1
Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells	1	PIEZO1

Dominant GO biological processes

GO term	Targets
monoatomic cation transport	1
positive regulation of myotube differentiation	1
positive regulation of integrin activation	1
positive regulation of cell-cell adhesion mediated by integrin	1
regulation of membrane potential	1
detection of mechanical stimulus	1
cellular response to mechanical stimulus	1
monoatomic ion transport	1
monoatomic ion transmembrane transport	1
monoatomic cation transmembrane transport	1

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
gout	4	MONDO:0005393	EFO:0004274

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE4	3
PHASE2	3
Not specified	2
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00422318	PHASE4	COMPLETED	Treatment of Hyperuricemia in Patients With Heart Failure
NCT03534037	PHASE4	UNKNOWN	Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction
NCT05210517	PHASE4	COMPLETED	SGLT2 Inhibition: Uric Acid Excretion Study
NCT03100318	PHASE3	COMPLETED	Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout
NCT02317861	PHASE1/PHASE2	COMPLETED	A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
NCT02790450	PHASE2	COMPLETED	Acute Effects of Benzbromaron on the Pulmonary Circulation
NCT03185793	PHASE2	COMPLETED	Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia
NCT05504083	PHASE2	COMPLETED	Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients
NCT02338323	Not specified	COMPLETED	Compare the Renal Protective Effects of Febuxostat and Benzbromarone
NCT02944214	Not specified	UNKNOWN	Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 0 clinical and 2 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).